Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 3/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
MAB Stock Overview
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland.
Mabion Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | zł27.60 |
52 Week High | zł110.00 |
52 Week Low | zł22.60 |
Beta | 0.75 |
1 Month Change | -1.43% |
3 Month Change | -5.80% |
1 Year Change | -54.75% |
3 Year Change | -63.25% |
5 Year Change | -70.95% |
Change since IPO | 104.75% |
Recent News & Updates
Is Mabion (WSE:MAB) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Mabion S.A. (WSE:MAB) Shares Could Be 47% Below Their Intrinsic Value Estimate
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Mabion S.A. ( WSE:MAB...
Shareholder Returns
MAB | PL Biotechs | PL Market | |
---|---|---|---|
7D | 1.7% | -1.7% | 6.3% |
1Y | -54.8% | -39.0% | -42.2% |
Return vs Industry: MAB underperformed the Polish Biotechs industry which returned -39% over the past year.
Return vs Market: MAB underperformed the Polish Market which returned -42.2% over the past year.
Price Volatility
MAB volatility | |
---|---|
MAB Average Weekly Movement | 14.2% |
Biotechs Industry Average Movement | 7.1% |
Market Average Movement | 6.8% |
10% most volatile stocks in PL Market | 13.4% |
10% least volatile stocks in PL Market | 4.5% |
Stable Share Price: MAB is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: MAB's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 213 | Krzysztof Kaczmarczyk | https://www.mabion.eu |
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of malignant, autoimmune, and metabolic diseases. Its products include MabionCD20, MabionHER2, MabionEGFR, and MabionVEGF that are oncology drugs; and MabionVEGF_Fab to treat several diseases resulting in vision impairment.
Mabion Fundamentals Summary
MAB fundamental statistics | |
---|---|
Market Cap | zł446.07m |
Earnings (TTM) | zł1.90m |
Revenue (TTM) | zł56.87m |
234.4x
P/E Ratio7.8x
P/S RatioIs MAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MAB income statement (TTM) | |
---|---|
Revenue | zł56.87m |
Cost of Revenue | zł0 |
Gross Profit | zł56.87m |
Other Expenses | zł54.97m |
Earnings | zł1.90m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
May 27, 2022
Earnings per share (EPS) | 0.12 |
Gross Margin | 100.00% |
Net Profit Margin | 3.35% |
Debt/Equity Ratio | 120.9% |
How did MAB perform over the long term?
See historical performance and comparisonValuation
Is Mabion undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
234.41x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MAB (PLN27.6) is trading above our estimate of fair value (PLN11.67)
Significantly Below Fair Value: MAB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MAB is poor value based on its Price-To-Earnings Ratio (234.4x) compared to the Polish Biotechs industry average (35x).
PE vs Market: MAB is poor value based on its Price-To-Earnings Ratio (234.4x) compared to the Polish market (10.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MAB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MAB is overvalued based on its Price-To-Book Ratio (27.5x) compared to the PL Biotechs industry average (3.8x).
Future Growth
How is Mabion forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
15.3%
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if MAB's forecast earnings growth is above the savings rate (2.5%).
Earnings vs Market: Insufficient data to determine if MAB's earnings are forecast to grow faster than the Polish market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MAB's revenue (15.3% per year) is forecast to grow faster than the Polish market (5.5% per year).
High Growth Revenue: MAB's revenue (15.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MAB's Return on Equity is forecast to be high in 3 years time (26.9%)
Past Performance
How has Mabion performed over the past 5 years?
Past Performance Score
3/6Past Performance Score 3/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
7.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MAB has high quality earnings.
Growing Profit Margin: MAB became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: MAB has become profitable over the past 5 years, growing earnings by 7.8% per year.
Accelerating Growth: MAB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MAB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: MAB's Return on Equity (11.7%) is considered low.
Financial Health
How is Mabion's financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: MAB's short term assets (PLN112.7M) do not cover its short term liabilities (PLN118.5M).
Long Term Liabilities: MAB's short term assets (PLN112.7M) exceed its long term liabilities (PLN57.4M).
Debt to Equity History and Analysis
Debt Level: MAB has more cash than its total debt.
Reducing Debt: MAB's debt to equity ratio has reduced from 352% to 120.9% over the past 5 years.
Debt Coverage: MAB's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if MAB's interest payments on its debt are well covered by EBIT.
Balance Sheet
Dividend
What is Mabion current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
1.85%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MAB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MAB has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
zł104k
CEO Compensation
CEO
Krzysztof Kaczmarczyk
1
Tenure
zł104,000
Compensation
Mr. Krzysztof Kaczmarczyk serves as Non-Executive Independent Director of Huuuge, Inc. He had been a Supervisory Board Member at CI Games S.A. until 2022. He served as an Independent Chairman of the Superv...
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Mabion S.A.'s employee growth, exchange listings and data sources
Key Information
- Name: Mabion S.A.
- Ticker: MAB
- Exchange: WSE
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: zł446.066m
- Shares outstanding: 16.16m
- Website: https://www.mabion.eu
Number of Employees
Location
- Mabion S.A.
- gen. Mariana Langiewicza 60 Street
- Konstantynów Lódzki
- 95-050
- Poland
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/26 00:00 |
End of Day Share Price | 2022/05/26 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.